title: No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study.
abstract: BACKGROUND
  Increased homocysteine levels are related to the occurrence of venous thrombosis, but whether this relation is causal is unclear. The T-variant of the common methylenetetrahydrofolate reductase (MTHFR) 677C-->T polymorphism mildly increases homocysteine levels. Meta-analyses have demonstrated a weak effect of the MTHFR 677TT genotype on risk but are sensitive to selective publication of positive results. The aim of the present study was to evaluate the effect of the MTHFR genotype on the risk of venous thrombosis, overall and in subgroups of known risk factors, in a single large study.
  
  
  METHODS
  In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA Study), a population-based case-control study, we collected DNA from 4375 patients with a first deep vein thrombosis of the leg or pulmonary embolism and from 4856 control subjects. Information about risk factors for venous thrombosis was obtained from questionnaires.
  
  
  RESULTS
  MTHFR 677C-->T was not associated with the risk of venous thrombosis (odds ratio [95% confidence interval], 0.99 [0.91-1.08] for the CT genotype and 0.94 [0.81-1.08] for the TT genotype). Stratification by known risk factors for venous thrombosis provided no evidence of an association in specific groups.
  
  
  CONCLUSIONS
  In a single large study, MTHFR 677C-->T was not associated with the risk of venous thrombosis, and the narrow confidence interval excludes even a small effect. Therefore, mildly elevated homocysteine levels as a result of MTHFR 677TT do not seem to cause venous thrombosis. There is no rationale for measuring the MTHFR 677C-->T variant for clinical purposes.
authors.affiliation: Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
authors.forename: Irene D
authors.initials: ID
authors.lastname: Bezemer
authors.forename: Carine J M
authors.initials: CJ
authors.lastname: Doggen
authors.forename: Hans L
authors.initials: HL
authors.lastname: Vos
authors.forename: Frits R
authors.initials: FR
authors.lastname: Rosendaal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D015415:Biomarkers / Q000097:blood; D004247:DNA / Q000235:genetics*; D005165:Factor V / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006710:Homocysteine / Q000097:blood; D006801:Humans; D015994:Incidence; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011379:Prognosis; D011516:Prothrombin / Q000235:genetics / Q000378:metabolism; D011655:Pulmonary Embolism / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D020246:Venous Thrombosis / Q000097:blood / Q000453:epidemiology / Q000235:genetics*
chemical_list: D015415:Biomarkers; C095381:factor V Leiden; D006710:Homocysteine; D005165:Factor V; D011516:Prothrombin; D004247:DNA; D042965:Methylenetetrahydrofolate Reductase (NADPH2)